* I-STEM *
2005 - IDF
Évry
(near Paris)
www.istem.eu Discovery, Drugs
(also, Contract, Research)
Key words: Stem cells, Monogenic diseases, Drug Discovery, Cell therapy, Pathological modelling, HTS & HCS
Mission: to develop new treatments based on the potential offered by pluripotent stem cells (human embryonic cells and iPS) and applicable to rare diseases of genetic origin
Clients: undisclosed
lgrannec@istem.genethon.fr
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Start-up |
Managing Dir.: Peschanski (Marc)
Sc.Dir.: Peschanski (Marc)
Fin.Dir.: Zakhia (Raymond)
BusDev: Hechard (Céline)
Financers: INSERM, AFM (French Muscular Dystrophy Association)
Note : a public-private Institute equally funded by INSERM and AFM, on a yearly budget (about 7 M€ each year between 2005 and 2008) | Turnover (M€) : n.a.
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Incub
Company confirm : 30-Oct-2008 |
History | DATE | MILESTONE | TYPE | TIME | | 2007 .01 | Set-up of mixed Inserm-UEVE (Université d’Évry-Val d’Essonne) R&D unit | ORGC | [2 years] |
| 2005 .01 | Company founded by INSERM and AFM(French Muscular Dystrophy Association), as Institute for Stem cell Therapy and Exploration of Monogenic diseases (I-Stem) | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
